Ampullary Cancer: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Ampullary carcinoma is a rare periampullary malignancy arising at the ampulla of Vater — the anatomical confluence of the common bile duct and the main pancreatic duct at their shared opening into the second part of the duodenum. It accounts for approximately 0.2% of gastrointestinal cancers globally and represents 5-10% of periampullary malignancies (the remainder being pancreatic head adenocarcinoma, distal cholangiocarcinoma, and duodenal adenocarcinoma). Ampullary carcinoma is clinically important because it presents earlier than pancreatic cancer (early biliary obstruction from the narrow ampullary lumen) and carries a substantially better prognosis — 5-year overall survival of 45-55% for resected disease, compared to approximately 25-30% for resected pancreatic cancer. Two distinct histological and molecular subtypes exist: intestinal-type (resembling colorectal adenocarcinoma in architecture, immunohistochemistry, and molecular alterations including KRAS mutations, favorable prognosis) and pancreatobiliary-type (resembling cholangiocarcinoma or pancreatic cancer, more aggressive behavior, worse prognosis). These subtypes have distinct chemotherapy responses, making molecular subtyping clinically relevant for systemic therapy selection. NCCN guidelines recommend comprehensive molecular profiling including MSI/MMR status, KRAS/NRAS/BRAF, HER2, and NTRK at diagnosis for all ampullary adenocarcinomas.

Ampullary carcinoma predominantly arises through the adenoma-carcinoma sequence — malignant transformation of pre-existing ampullary or periampullary adenomas through progressive acquisition of somatic mutations. Hereditary syndromes substantially increase risk. Familial adenomatous polyposis (FAP, APC germline mutation on chromosome 5q21-22): over 60% of FAP patients develop duodenal adenomatosis (Spigelman classification I-IV based on adenoma number, size, and histology), with ampullary adenomas in approximately 10-30%; the cumulative lifetime ampullary cancer risk in FAP is approximately 4-12%, making periampullary surveillance as critical as colorectal surveillance after prophylactic colectomy. Lynch syndrome (germline MMR gene mutations — MLH1, MSH2, MSH6, PMS2): confers elevated duodenal and ampullary cancer risk with MSI-H tumors (approximately 10-15% of ampullary cancers are MSI-H) that respond to pembrolizumab immunotherapy. MUTYH-associated polyposis: modest ampullary cancer risk. Chronic pancreatitis and choledocholithiasis: chronic biliary epithelial irritation may predispose to periampullary dysplasia. The majority of sporadic ampullary adenocarcinomas arise without identifiable hereditary predisposition. Key somatic alterations: KRAS mutations (~40% of intestinal-type, ~50% of pancreatobiliary-type), HER2 amplification (~20%), TP53 mutations, SMAD4 loss, and CDKN2A loss.

Ampullary carcinoma typically presents earlier than pancreatic cancer because the narrow ampullary orifice is obstructed by smaller tumors, producing biliary symptoms at a resectable stage. Painless obstructive jaundice is the cardinal presenting symptom, occurring in approximately 80% of patients — progressive yellowing of the skin and sclera accompanied by dark urine (bilirubinuria), pale clay-colored stools, and generalized pruritus (from bile salt deposition in the skin). Jaundice from ampullary cancer may characteristically fluctuate or partially remit (owing to intermittent ulceration or necrosis of the tumor allowing bile to drain), a pattern less typical of pancreatic cancer. Epigastric pain or discomfort radiating to the back may occur. Acute pancreatitis: ampullary tumor obstructing the pancreatic duct can precipitate acute or recurrent pancreatitis — an important presenting feature. Upper gastrointestinal bleeding: ampullary tumors may ulcerate and bleed, presenting as melaena or hematemesis, or as iron-deficiency anemia. Nausea, vomiting, and anorexia with associated weight loss occur in larger or locally advanced tumors. Courvoisier's sign — a palpable, non-tender, distended gallbladder in the context of obstructive jaundice — suggests extrahepatic biliary obstruction from a periampullary mass (present in approximately 25% of cases). CA 19-9 and CEA are elevated in approximately 50-70% of ampullary cancers.

Upper GI endoscopy with side-viewing duodenoscope (ERCP endoscope) allows direct visualization of the ampulla and targeted biopsy of suspicious lesions — this is the most sensitive approach for detecting ampullary tumors. CT pancreatic protocol (thin-slice contrast-enhanced CT with arterial and portal-venous phases) provides accurate assessment of local tumor extent, vascular involvement (superior mesenteric artery and vein encasement — key resectability criteria), and distant staging (liver, peritoneal). MRI/MRCP provides additional soft tissue characterization and biliary anatomy delineation. EUS (endoscopic ultrasound): superior T staging accuracy (T1-T4) and regional lymph node (N) assessment; EUS-FNA for tissue sampling if endoscopic biopsy is non-diagnostic. Biliary stenting (plastic stent for preoperative biliary decompression, metallic stent for palliation) via ERCP. AJCC 8th edition TNM staging: T1a (limited to sphincter of Oddi), T1b (beyond sphincter into duodenal submucosa), T2 (duodenal muscularis propria), T3a (pancreatic parenchyma <0.5 cm), T3b (>0.5 cm into pancreas or peripancreatic tissue), T4 (adjacent organs). Mandatory comprehensive molecular profiling for all resected and metastatic ampullary adenocarcinomas: MSI/MMR status (IHC and/or PCR), KRAS/NRAS exons 2-4, BRAF V600E, HER2 amplification by FISH or NGS, NTRK1/2/3 fusion, and TMB — these determine eligibility for pembrolizumab, HER2-targeted therapy, larotrectinib, and anti-EGFR agents.

Resectable ampullary adenocarcinoma: pancreaticoduodenectomy (Whipple procedure) with regional lymphadenectomy (minimum 12 lymph nodes) is the standard curative surgery — pylorus-preserving Whipple (PPPD) is equally oncological and is now preferred at most centers; standard open or minimally invasive (laparoscopic or robotic) approaches are available. Perioperative biliary drainage: preoperative ERCP stenting for jaundiced patients (bilirubin above 250 μmol/L) to reduce surgical risk; metal stents preferred if surgery is delayed more than 4 weeks. Adjuvant chemotherapy: FOLFOX (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus plus 2400 mg/m2 infusion over 46 hours, every 2 weeks for 6 months) — supported by the ESPAC-3 trial (superior DFS to observation); capecitabine 1250 mg/m2 BD for 14 days every 21 days for 6 months is an alternative. Adjuvant gemcitabine plus capecitabine is used at some centers based on extrapolation from ESPAC-4 pancreatic data. Locally advanced or metastatic ampullary cancer: first-line FOLFOX or FOLFIRI; KRAS wild-type intestinal subtype: consider cetuximab or panitumumab addition (by analogy with colorectal cancer, awaiting prospective ampullary-specific data). MSI-H/dMMR: pembrolizumab 200 mg every 3 weeks (first-line or subsequent lines — significant durable responses documented). HER2-amplified: trastuzumab-based regimen or trastuzumab deruxtecan (T-DXd) for HER2-positive refractory disease. NTRK fusion-positive: larotrectinib or entrectinib. Endoscopic ampullectomy: curative approach for high-grade ampullary adenoma or T1a ampullary cancer in carefully selected patients at expert endoscopic centers.

Ampullary carcinoma has a significantly better prognosis than pancreatic cancer despite sharing the Whipple procedure as the primary surgical approach. Overall 5-year survival for all resected ampullary adenocarcinoma is approximately 45-55%, substantially better than the approximately 25-30% seen for resected pancreatic cancer. Histological subtype is the most important prognostic factor: intestinal-type ampullary cancer carries 5-year survival of approximately 60-70% after complete resection, while pancreatobiliary-type carries approximately 25-40%. Stage I (T1a/b, N0): 5-year survival approximately 65-75%; Stage II (T2-T3, N0): approximately 45-55%; Stage III (any T, N1): approximately 25-40%; Stage IV (distant metastases): approximately 5-15%. Lymph node involvement significantly worsens prognosis — node-negative resected disease carries approximately 60-70% 5-year survival versus approximately 30-40% for node-positive. R0 surgical margin status is essential — positive margins are associated with early recurrence and poor outcome. MSI-H ampullary cancers have intrinsically favorable biology and respond durably to pembrolizumab immunotherapy. Recurrence occurs in approximately 30-50% of resected patients, predominantly in the liver and peritoneum, with the majority of recurrences within the first 3 years. Adjuvant FOLFOX chemotherapy improves relapse-free survival. Long-term survivors require surveillance with CA 19-9, CEA, and CT imaging at 6-monthly intervals for the first 3 years and annually thereafter. Quality of life following Whipple procedure is generally good at 1-2 years post-surgery in experienced hepatopancreaticobiliary centers.

Most ampullary cancers arise from adenomas through the adenoma-carcinoma sequence, offering a window for endoscopic surveillance and intervention. Patients with FAP must undergo regular upper GI endoscopy including ampullary inspection every 1-3 years based on the Spigelman classification of duodenal polyposis severity — this is as important as colorectal surveillance after prophylactic colectomy. Lynch syndrome carriers should include upper endoscopy in their cancer surveillance programme. Endoscopic ampullectomy can successfully treat ampullary adenomas before malignant transformation, preventing progression to invasive cancer. There are no established dietary or lifestyle interventions specifically preventing ampullary cancer, though maintaining a healthy weight and avoiding tobacco reduces general gastrointestinal cancer risk.

Painless progressive jaundice — yellowing of the skin and whites of the eyes, often accompanied by dark urine and pale stools — should prompt urgent evaluation. Because ampullary cancer causes obstructive jaundice at an earlier stage than pancreatic cancer, it offers an important opportunity for early diagnosis and potentially curative surgery. Unexplained acute pancreatitis, particularly recurring episodes, should include evaluation of the ampullary region by ERCP or EUS. Upper gastrointestinal bleeding or iron-deficiency anaemia of unknown origin warrants upper endoscopy. Patients with known FAP or Lynch syndrome should adhere rigorously to their endoscopic surveillance schedule, as surveillance-detected ampullary adenomas can be removed endoscopically before becoming cancer. Unexplained weight loss or epigastric pain radiating to the back also warrants investigation.